Q-omics provides the consensus-scored PTP4A1P3 profile across patient tissues and cancer cell-line models. PTP4A1P3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PTP4A1P3 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, PTP4A1P3 RNA expression shows 12,413 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where PTP4A1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTP4A1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTP4A1P3 survival associations across molecular data types. PTP4A1P3 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTP4A1P3 RNA expression–survival associations across cancer types. High PTP4A1P3 expression shows unfavorable associations in MESO, ACC, PCPG, THYM and BLCA, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PTP4A1P3 RNA expression.
This table summarizes PTP4A1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PTP4A1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTP4A1P3 shows higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher PTP4A1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .010).
This table shows molecular features associated with PTP4A1P3 in patient tissues and cancer cell lines. In patient samples, PTP4A1P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
